Prognostic significance of Bcl-2 in clinically localized prostate cancer

American Journal of Pathology

Volumn 148, Issue 5, 1996, Pages 1557-1565

  Bubendorf, Lukas ^a   Sauter, Guido ^a   Moch, Holger ^a   Jordan, Paul ^a   Blöchlinger, Andrea ^a   Gasser, Thomas C ^a   Mihatsch, Michael J ^a  

^a UNIVERSITY OF BASEL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ONCOPROTEIN; PROTEIN P53;

ADULT; AGED; APOPTOSIS; ARTICLE; CANCER SURVIVAL; DISEASE COURSE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PROSTATECTOMY; TUMOR GROWTH;

AGED; AGED, 80 AND OVER; APOPTOSIS; CELL DIVISION; DISEASE PROGRESSION; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; LINEAR MODELS; MALE; MIDDLE AGED; NEOPLASM PROTEINS; NUCLEAR PROTEINS; PHENOTYPE; PROGNOSIS; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0030008078     PISSN: 00029440     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (63)

1. Muir CS, Nectoux J, Staszewski J The epidemiology of prostatic cancer geographical distribution and time-trends. Acta Oncol 1991, 30:133-140
2. Rinker-Schaeffer CW, Partin AW, Isaacs WB, Coffey DS, Isaacs JT. Molecular and cellular changes associated with the acquisition of metastatic ability by prostatic cancer cells Prostate 1994, 25:249-265
3. Kerr JFR, Winterford CM, Harmon BV: Apoptosis. Cancer 1993, 73:2013-2026
4. Korsmeyer SJ. Bcl-2 initiates a new category of oncogenes, regulators of cell death. Blood 1992, 80: 879-886
5. Hockenbery D, Nunez G, Milliman C, Schreiber RD, Korsmeyer SJ. Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death Nature 1990, 348 334-336
6. Bronner MP, Culin C, Reed JC, Furth EE: The bcl-2 proto-oncogene and the gastrointestinal epithelial tumor progression model Am J Pathol 1995, 146:20-26
7. Bosari S, Moneghini L, Graziani D, Lee AKC, Murray JJ, Coggi G, Viale G: Bcl-2 oncoprotein in colorectal hyperplastic polyps, adenomas, and adenocarcinomas. Hum Pathol 1995, 26:534-540
8. Chandler D, El-Naggar AK, Brisbay S, Redline RW, McDonnell TJ: Apoptosis and expression of the bcl-2 protooncogene in the fetal and adult human kidney, evidence for the contribution of bcl-2 expression to renal carcinogenesis. Hum Pathol 1994, 25 789-796
9. Castle VP, Heidelberger KP, Bromberg J, Ou X, Dole M, Nunez G. Expression of the apoptosis-suppressing protein Bcl-2 in neuroblastoma is associated with unfavorable histology and N-myc amplification. Am J Pathol 1993, 143:1543-1550
10. Joensuu H, Phylkkänen L, Toikkanen S. Bcl-2 protein expression and long-term survival in breast cancer. Am J Pathol 1994, 145:1191-1198
11. Viale G, Roncalli M, Grimelius L, Graziani D, Wilander E, Johansson H, Bergholm U, Coggi G: Prognostic value of Bcl-2 immunoreactivity in medullary thyroid carcinoma Hum Pathol 1995, 26:945-950
12. Pezzella F, Turley H, Kuzu I, Tungekar MF, Dunnill MS, Pierce CB, Harris A, Gatter KC, Mason DJ. bcl-2 protein in non-small-cell lung carcinoma N Engl J Med 1993, 329:690-694
13. McDonnell TJ, Troncoso P, Brisbay SM, Logothetis C, Chung LWK, Hsieh JT, Tu SM, Campbell ML: Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer. Cancer Res 1992, 52 6940-6944
14. Colombel M, Symmans F, Gil SO, TMK, Chopin D, Benson M, Olsson CA, Korsmeyer S, Buttyan R: Detection of the apoptosis-suppressing oncoprotein Bcl-2 in hormone-refractory human prostate cancers Am J Pathol 1993, 143:390-400
15. Westin P, Stattin P, Damber J, Bergh A: Castration therapy rapidly induces apoptosis in a minority and decreases cell proliferation in a majority of human prostatic tumors Am J Pathol 1995, 146:1368-1375
16. Raffo AJ, Perlman H, Chen MW, Day ML, Streitman JS, Buttyan R Overexpression of bcl-2 protects prostate cancer cells from apoptosis in vitro and confers resistance to androgen depletion in vivo Cancer Res 1995, 55:4438-4445
17. Vogelstein B, Kinzler KW: p53 function and dysfunction Cell 1992, 70 523-526
18. Levine AJ, Momand J, Finlay CA: The p53 tumour suppressor gene. Nature 1991, 351:453-456
19. Finlay C, Hinds P, Tan T, Eliyahu D, Oren M, Levine A Activating mutations for transformation by p53 produce a gene product that forms a hsc70-p53 complex with an altered half-life. Moll Cell Biol 1988, 8:531-539
20. Navone NM, Troncoso P, Pisters LL, Goodrow TL, Palmer JL, Nichols WW, Von EAC, Conti CJ: p53 protein accumulation and gene mutation in the progression of human prostate carcinoma J Natl Cancer Inst 1993, 85:1657-1669
21. Bookstein R, MacGrogan D, Hilsenbeck SG, Sharkey F, Allred DC p53 is mutated in a subset of advanced-stage prostate cancers. Cancer Res 1993, 53:3369-3373
22. Hall PA, Lane DP: p53 in tumor pathology: can we trust immunohistochemistry? Revisited! J Pathol 1994, 172: 1-4
23. Thor AD, Yandell DW: Prognostic significance of p53 overexpression in node-negative breast carcinoma. J Natl Cancer Inst 1993, 85 176-177
24. Dalquen P, Sauter G, Torhorst J, Schultheiss E, Jordan P, Lehmann S, Soler M, Stulz P, Mihatsch MJ, Gudai F: Nuclear p53 overexpression is an independent prognostic parameter in node-negative non-small-cell lung cancer. J Pathol 1996, 178:53-58
25. Esrig D, Elmajian D, Groshen S, Freeman JA, Stein JP, Chen S, Nichols PW, Skinner DG, Jones PA, Cote RJ: Accumulation of nuclear p53 and tumor progression in bladder cancer. N Engl J Med 1994, 331:1259-1264
26. Lee JS, Yoon A, Kalapurakal SK, Ro JY, Lee JJ, Tu N, Hittelmann W, Hong WK. Expression of p53 oncoprotein in non-small-cell lung cancer: a favorable prognostic factor. J Clin Oncol 1995, 13:1893-1903
27. Rosen PP, Lesser ML, Arroyo CD, Milicent C, Borgen P, Norton L p53 in node-negative breast carcinoma, an immunohistochemical study of epidemiologic risk factors, histologic features, and prognosis. J Clin Oncol 1995, 13:821-830
28. Myers RB, Oelschlager D, Srivastava S, Grizzle WE Accumulation of the p53 protein occurs more frequently in metastatic than in localized prostatic adenocarcinomas. Prostate 1994, 25:243-248
29. Thomas DJ, Robinson M, King P, Hasan T, Charlton R, Martin J, Carr TW, Neal DE: p53 expression and clinical outcome in prostate cancer Br J Urol 1993, 72:778-781
30. Visakorpi T, Kallioniemi OP, Heikkinen A, Koivula T, Isola J: Small subgroup of aggressive, highly proliferative prostatic carcinomas defined by p53 accumulation. J Natl Cancer Inst 1992, 84 883-887
31. Shurbaji MS, Kalbfleisch KH, Thurmond TS: Immunohistochemical detection of p53 protein as a prognostic indicator in prostate cancer. Hum Pathol 1995, 26 106-109
32. Bauer JJ, Sesterhenn IA, Mostofi KF, McLeod DG, Srivastava S, Moul JW. p53 nuclear protein expression is an independent prognostic marker in clinically localized prostate cancer patients undergoing radical prostatectomy. Clin Cancer Res 1995, 1:1295-1300
33. International Union Against Cancer (UICC): Classification of Malignant Tumours, ed 4, revision 2 Berlin, Springer, 1992
34. Gleason DF: Histologic grading and clinical staging of prostatic carcinoma Urologic Pathology. The Prostate Edited by M Tannenbaum. Philadelphia, Lea and Febiger, 1977, pp 171-197
35. Gasparini G, Barbareschi M, DallaPalma P, Mauri FA Boracchi P, Bevilacqua P, Caffo O, Morelli L, Verderio P, Pezzella F, Harris AL: Expression of Bcl-2 protein predicts efficacy of adjuvant treatments in operable node-positive breast cancer. Clin Cancer Res 1995, 1:189-198
36. Bhargava V, Kell DL, van de Rijn M, Warnke RA: Bcl-2 immunoreactivity in breast carcinoma correlates with hormone receptor positivity Am J Pathol 1994, 145 535-540
37. Sauter G, Deng G, Moch H, Kerschmann R, Matsumura K, DeVries S, George T, Fuentes J, Carroll P, Mihatsch MJ, Waldman FM. Physical deletion of the p53 gene in bladder cancer: detection by fluorescence in situ hybridization. Am J Pathol 1994, 144:756-766
38. Moch H, Sauter G, Epper R, Mihatsch M, Gudat F, Waldman F. p53 but not erb-B2 expression is associated with rapid tumor cell proliferation in urinary bladder cancer. Hum Pathol 1994, 25:1346-1351
39. Bubendorf L, Sauter G, Moch H, Schmid HP, Gasser TC, Jordan P, Mihatsch JM: Ki67 labeling index, an independent predictor of progression in prostate cancer treated by radical prostatectomy J Pathol (in press)
40. Segal NH, Cohen RJ, Haffejee Z, Savage N. BLC-2 proto-oncogene expression in prostate cancer and its relationship to the prostatic neuroendocrine cell. Arch Pathol Lab Med 1994, 118:616-618
41. Lange PH, Ercole CJ, Lightner DJ, Fraley EE, Vessella R: The value of serum prostate specific antigen determinations before and after radical prostatectomy J Urol 1989, 141:873-879
42. Partin AW, Pound CR, Clemens JQ, Epstein JI, Walsh PC: Serum PSA after anatomic radical prostatectomy the Johns Hopkins experience after 10 years Urol Clin North Am 1993, 20:713-725
43. Catalona WJ. Surgical management of prostate cancer. Cancer 1995, 75 1903-1908
44. Epstein JI, Pizov G, Walsh PC. Correlation of pathologic findings with progression after radical retropubic prostatectomy. Cancer 1993, 71 3582-3593
45. Humphrey PA, Walther PJ: Adenocarcinoma of the prostate II Tissue prognosticators. Am J Clin Pathol 1993, 100:256-269
46. Strasser A, Harris AW, Jacks T, Cory S: DNA damage can induce apoptosis in proliferating lymphoid cells via p53-independent mechanisms inhibitable by Bcl-2. Cell 1994, 79:329-339
47. Livingstone LR, White A, Sprouse J, Livanos E, Jacks T, Tlsty TD: Altered cell cycle arrest and gene amplification potential accompany loss of wild-type p53 Cell 1992, 70:923-935
48. Vaux D, Gory S, Adams J: Bcl-gene promotes haemopoietic cell survival and cooporates with c-myc to immortalize pre-B cells. Nature 1988, 335 440-442
49. Mapara M, Bargou R, Zugck C, Döhner H, Ustaoglu F, Krammer PH, Dörken P: APO-1 mediated apoptosis or proliferation in human chronic B lymphocytic leukemia: correlation with bcl-2 oncogene expression. Eur J Immunol 1993, 23 702-708
50. Owen-Schaub L, Radinsky R, Kruzel E, Berry K, Yonehara S. Anti-Fas on non-hematopoietic tumors: levels of Fas/APO-1 and Bcl-2 are not predictive of biological responsiveness Cancer Res 1994, 54:1580-1586
51. Oltvai ZN, Millimann CL, Korsmeyer SJ. Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell 1993, 74:609-619
52. Boise LH, Gonzáles-García M, Postema CE, Ding L, Lindsten T, Turka LA, Mao X, Nuñez G, Thompson CB: bcl-X, a bcl-2-related gene that functions as a dominant regulator of apoptotic cell death. Cell 1993, 74:597-608
53. Takayama S, Takaaki S, Krajewski S, Kochel K, Irie S, Millan JA, Reed JC: Cloning and functional analysis of BAG-1: a novel Bcl-2 binding protein with anti-cell death activity. Cell 1995, 80:279-284
54. Visakorpi T: Proliferates activity determined by DNA flow cytometry and proliferating cell nuclear antigen (PCNA) immunohistochemistry as a prognostic factor in prostatic carcinoma J Pathol 1992, 168 7-13
55. Harper ME, Glynne JE, Goddard L, Wilson DW, Matenhelia SS, Conn IG, Peeling WB, Griffiths K: Relationship of proliferating cell nuclear antigen (PCNA) in prostatic carcinomas to various clinical parameters Prostate 1992, 20:243-253
56. Hollstein M, Sidransky D, Vogelstein B, Harris CC. p53 mutations in human cancers. Science 1991, 253:49-53
57. Aprikian AG, Sarkis AS, Fair WR, Zhang ZF, Fuks Z, Cordon CC. Immunohistochemical determination of p53 protein nuclear accumulation in prostatic adenocarcinoma J Urol 1994, 151:1276-1280
58. Thompson SJ, Mellon K, Charlton G, Marsh C, Robinson M, Neal DE: p53 and Ki-67 immunoreactivity in human prostate cancer and benign hyperplasia. Br J Urol 1992, 69:609-613
59. Vesalainen SL, Lipponen PK, Talja MT, Aihava EM, Syrjanen KJ: Proliferating cell nuclear antigen and p53 expression as prognostic factors in T1-2MO prostatic adenocarcinoma. Int J Cancer 1994, 58:303-308
60. Kallakury BVS, Figge J, Ross JS, Fisher HAG, Figge HL, Jennings TA: Association of p53 immunoreactivity with high Gleason tumor grade in prostatic adenocarcinoma Hum Pathol 1994, 25:92-97
61. Wang Y, Szekely L, Klein G, Wiman KG. Wild-type p53-triggered apoptosis is inhibited by bcl-2 in a v-myc-induced T-cell lymphoma line. Oncogene 1993, 8 3427-3431
62. Miyashita T, Krajewski S, Krajewska M, Wang HG, Lin HK, Liebermann DA, Hoffmann B, Reed JC: Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo. Oncogene 1994, 9:1799-1805
63. Ohori M, Wheeler TM, Scardino PT: The new American joint committee on cancer and international union against cancer TNM classification of prostate cancer. Cancer 1994, 74:104-114